Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells

Hepatology

Volumn 54, Issue 6, 2011, Pages 1901-1912

  Andrus, Linda ^a   Marukian, Svetlana ^a   Jones, Christopher T ^a   Catanese, Maria Teresa ^a   Sheahan, Timothy P ^a   Schoggins, John W ^a   Barry, Walter T ^a   Dustin, Lynn B ^a   Trehan, Kartik ^b   Ploss, Alexander ^a   Bhatia, Sangeeta N ^b   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; LENTIVIRUS VECTOR; LUCIFERASE; VIRUS PROTEIN V; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; FETUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INFECTION CONTROL; LIVER CELL; MEASLES VIRUS; NONHUMAN; PARAMYXOVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; SIMIAN PARAINFLUENZA VIRUS 5; VIRAL CLEARANCE; VIRUS REPLICATION; VIRUS VIRULENCE;

HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERONS; INTERLEUKINS; LENTIVIRUS; LIVER; PRIMARY CELL CULTURE; TRANSDUCTION, GENETIC; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 82455175215     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24557     Document Type: Article

References (40)

1. Altar HJ, Seeff LB. Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on the long-term outcome. Semin Liv Dis 2000; 20: 17-25.
2. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 2005; 102: 17717-17722.
3. Otsuka M, Kato N, Moriyama M, Taniguchi H, Wang Y, Dharel N, et al. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. HEPATOLOGY 2005; 41: 1004-1012.
4. Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA, et al. Hepatitis C virus core protein blocks interferon signaling by interaction with STAT1 SH2 domain. J Virol 2006; 80: 9226-9235.
5. Gale M, Foy EM. Evasion of intracellular host defense by hepatitis C virus. Nature 2005; 436: 939-945.
6. Iacovacci S, Manzin A, Barca S, Sargiacomo M, Serafino A, Valli MB, et al. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro. HEPATOLOGY 1997; 26: 1328-1337.
7. Lázaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, et al. Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol 2007; 170: 478-489.
8. Buck M. Direct infection and replication of naturally occurring hepatitis C virus Genotypes 1, 2, 3 1nd 4 in normal human hepatocyte cultures. PLoSone 2008; 3: e2660.
9. Ploss A, Khetani SP, Jones CT, Syder AJ, Ritola K, Rice CM, et al. Persistence of hepatitis C virus replication in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A 2010; 107: 341-345.
10. Podevin P, Carpentier A, Pene V, Aoudjehane L, Carriere M, Zaidi S, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroentrology 2010; 139: 1355-1364.
11. Banaudha K, Orenstein JM, Korolnek T, St Laurent GC, Wakita T, Kumar A. Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis. HEPATOLOGY 2010; 51: 1922-1932
12. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
13. Wakita T, Pietschmann T, Kato T, Data T, Miyamoto M. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
14. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetica and molecular determinants. J Virol 2010; 84: 34-43.
15. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in virus entry. Nature 2007: 446: 801-805.
16. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 2009; 83: 2011-2014.
17. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886.
18. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA mir-122. J Virol 2010; 84: 6615-6625.
19. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-1876.
20. Goodbourn S, Randall RE. The regulation of Type I interferon production by paramyxoviruses. J Interferon Cytokine Res 2009; 29: 539-547.
21. Ramachandran A, Horvath CM. Paramyxovirus disruption of interferon signal transduction: STATus report. J Interferon Cytokine Res 2009; 29: 531-537.
22. Childs K, Stock N, Ross C, Andrejeva J, Hilton L, Skinner M, et al. Mda5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 2007; 359: 190-200.
23. Parsien JP, Bamming D, Komuro A, Ramachandran A, Rodriguez JJ, Barber G, et al. A shared interface mediates paramyxovirus interference with antiviral RNA helicases MDA5 and LGP2. J Virol 2009; 83: 7252-7260.
24. Poole E, He B, Lamb RA, Randall RE, Goodbourn S. The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 2002; 303: 33-46.
25. Ramachandran A, Horvath CM. Dissociation of paramyxovirus interferon evasion activities: universal and virus-specific requirements for conserved V protein amino acids in MDA5 interference. J Virol 2010; 84: 11152-11163.
26. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
27. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type I interferon-like program to promote antiviral responses in human hepatocytes. HEPATOLOGY 2006: 44: 896-906.
28. Parisien JP, Lau JF, Rodriguez JJ, Ulane CM, Horvath CM. Selective STAT protein degradation induced by paramyxoviruses requires both STAT1 and STAT2 but is independent of alpha/beta interferon signal transduction. J Virol 2002; 76: 4190-4198.
29. Precious B, Childs K, Fitzpatrick-Swallow V, Goodbourn S, Randall RE. Simian virus 5 V protein acts as an adaptor, linking DDB1 to STAT2, to facilitate the ubiquitination of STAT1. J Virol 2005; 79: 13434-13441.
30. Palosaari H, Parisien JJ, Rodriguez CM, Horvath CM. STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. J Virol 2003; 77: 7635-7644.
31. Ramachandran A, Parisien JP, Horvath CM. STAT2 is a primary target for measles virus V protein-mediated alpha/beta interferon signaling inhibition. J Virol 2008; 82: 8330-8338.
32. Jones CT, Catanese MT, Law LM, Khetani SR, Syder AJ, Ploss A, et al. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotech 2010; 28: 167-171.
33. Schmeizer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007; 200: 1973-1987.
34. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse array of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-485.
35. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, Charles ED, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. HEPATOLOGY 2008; 48: 1843-1850.
36. Diamond DL, Syder AJ, Jacobs JM, Sorensen CM, Walters K-A, Proll SC, et al. Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathogens 2010; 6: e1000719.
37. Kohaar I, Ploss A, Korol E, Mu K, Schoggins JW, O'Brien TR, et al. Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry. J Virol 2010; 84: 6987-6994.
38. Inada M, Follenzi A, Cheng K, Surana M, Joseph B, Benten D, et al. Phenotype reversion in fetal human liver epithelial cells identifies the role of an intermediate mesoendodermal stage before hepatic maturation. J Cell Sci 2008; 1002-1013.
39. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, Rice CM, Dustin LB. Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology, in press.
40. Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, et al. Comparative analysis of the lambda-Interferons IL28A and IL2-9 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE 2010; 5: e15200.